Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenascienceTSE:4889 -2.25%53 FCF Yield % is -1.39 as of Jul. 16, 2026. GuruFocus rates TSE:4889 with a GF Score™ of 53/100 and a GF Value™ of 円331.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Renascience ranks worse than 53.8% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Renascience's FCF Yield % or its related term are showing as below:
TSE:4889'
s FCF Yield % Range Over the Past 10 Years
Min: -7.04 Med: -4.54 Max: -0.45
Current: -1.39
During the past 7 years, the highest FCF Yield % of Renascience was -0.45%. The lowest was -7.04%. And the median was -4.54%.
TSE:4889's FCF Yield % is ranked worse than 53.8% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.4
vs TSE:4889: -1.39
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Renascience FCF Yield % Related Terms
Renascience FCF Yield % Historical Data
* Premium members only.
The historical data trend for Renascience's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Renascience's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renascience FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Renascience's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Renascience's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renascience (TSE:4889) has a FCF Yield % of -1.39 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Renascience and its competitors. According to the industry distribution chart, Renascience ranks #460 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 53.8%.
Is Renascience's FCF Yield % too high?
Renascience's current FCF Yield % is -1.39. Based on the distribution chart, Renascience ranks #460 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Renascience has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Renascience ranks #460 out of 855 companies for FCF Yield %. This places Renascience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Renascience and its competitors. Renascience's current FCF Yield % is -1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円331.42, compared to a current price of 円1,522.00 — trading 359.2% above its estimated fair value. The current FCF Yield % is -1.39. Renascience's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Renascience (TSE:4889), the current FCF Yield % is -1.39 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renascience (TSE:4889) Overvalued in 2026?
Based on GuruFocus' analysis, Renascience stock appears to be overvalued.
The current stock price of 円1,522.00 is trading 359.2% above its estimated GF Value™ of 円331.42.
GuruFocus considers Renascience to be Significantly Overvalued.
Key valuation signals for TSE:4889:
FCF Yield %: -1.39
GF Value™: 円331.42 vs. price of 円1,522.00 (359.2% above fair value)
No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
53GF Score
Get the complete analysis for TSE:4889
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4889 has been successfully added to your 
